AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 293: E1069-E1077, 2007. First published July 31, 2007; doi:10.1152/ajpendo.00182.2007
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/4/E1069    most recent
00182.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Itoh, N.
Right arrow Articles by Nishimura, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Itoh, N.
Right arrow Articles by Nishimura, M.

Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes

Naofumi Itoh,1 Shinji Sakaue,1 Hiroaki Nakagawa,2 Masaki Kurogochi,2 Hiroshi Ohira,1 Kisaburo Deguchi,2 Shin-Ichiro Nishimura,2 and Masaharu Nishimura1

1First Department of Medicine, Graduate School of Medicine; and 2Graduate School of Advanced Life Science, Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Sapporo, Japan

Submitted 22 March 2007 ; accepted in final form 19 July 2007

Glycosylation has an important role in regulating properties of proteins and is associated with many diseases. To examine the alteration of serum N-glycans in type 2 diabetes, we used the db/db mouse model. Serum N-glycans were fluorescence labeled and applied to HPLC. There were reproducible differences in N-glycan profiles between the db/db mouse model and the db/+ control. The structures of the oligosaccharides, which had changed in their amounts, were analyzed by a two-dimensional mapping method, matrix-assisted laser desorption ionization-time-of-flight mass spectrometry, and exoglycosidase digestion. Those analyses revealed an increase in the N-glycans possessing {alpha}1,6-fucose in the serum of db/db mice. The level of {alpha}1,6-fucosyltransferase mRNA was increased in the liver of the db/db mice. The ratio of a biantennary N-glycan with {alpha}1,6-fucose to that without {alpha}1,6-fucose in the liver tissue of the db/db mouse was increased relative to the db/+ control. Next, we analyzed the serum N-glycan profile in human subjects with type 2 diabetes and found an increased amount of a biantennary N-glycan that had an {alpha}1,6-fucose with a bisecting N-acetylglucosamine. In conclusion, the increase in {alpha}1,6-fucosylation is a striking change in the serum N-glycans of the db/db mice, whereas the change in the fucosylation in humans with type 2 diabetes was small, albeit statistically significant. It is likely that the change is caused, at least partially, by the increase in the {alpha}1,6-fucosyltransferase mRNA level in the liver. The increased {alpha}1,6-fucosylation may affect protein properties associated with the pathophysiology of type 2 diabetes.

{alpha}1,6-fucosylation; {alpha}1,6-fucosyltransferase; liver


Address for reprint requests and other correspondence: S. Sakaue, First Dept. of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan (e-mail: sakaue-s{at}med.hokudai.ac.jp)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.